1 MOG-reactive B cells exacerbate the severity of CD4⁺ T cell-driven CNS
2 autoimmunity.

3

4 Prenitha Mercy Ignatius Arokia Doss¹, Asmita Pradeep Yeola¹, Benoit Mailhot¹,
 5 Joanie Baillargeon¹, Philippe Grenier², Steve Lacroix^{1,3}, Nicolas Bertrand^{2,4},
 6 Manu Rangachari^{1,3,5}.

7

8 ¹ axe Neurosciences, Centre de recherche du CHU de Québec – Université
 9 Laval, Pavillon CHUL, 2705 boul Laurier, Quebec City, QC, CANADA G1V 4G2; ²
 10 axe Endocrinologie et nephrologie, Centre de recherche du CHU de Québec –
 11 Université Laval, Pavillon CHUL, 2705 boul Laurier, Quebec City, QC, CANADA
 12 G1V 4G2; ³ Department of Molecular Medicine, Faculty of Medicine, Laval
 13 University, 1050 ave de la Médecine, Quebec City, CANADA; ⁴ Faculty of
 14 Pharmacy, Laval University, 1050 ave de la Médecine, Quebec City, CANADA; ⁵
 15 Corresponding author.

16

17

Abstract

BACKGROUND: Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) that has traditionally been considered T cell-mediated. However, accumulating evidence points to a crucial role for B cells in disease processes. Experimental autoimmune encephalomyelitis (EAE) is a well-established model to study the immune aspects of CNS autoimmunity.

METHODS: In order to examine the collaboration of B cells and T cells in EAE, we studied non-obese diabetic (NOD)-background IgH[MOG] mice, whose B cells express a transgenic IgH chain derived from a myelin oligodendrocyte glycoprotein (MOG)-specific antibody. We immunized these and NOD WT controls with the MHC class II-restricted peptide MOG_[35-55], which induces a CD4⁺ T cell-driven response. CNS tissue inflammation and demyelination were assessed histopathologically, and the phenotype of CNS-infiltrating mononuclear cells was studied by flow cytometry. The capacity of IgH[MOG] B cells to present antigen to CD4⁺ T cells was assessed using *in vitro* priming assays with MOG_[35-55] as the antigen.

RESULTS: MOG_[35-55]-immunized IgH[MOG] mice rapidly developed severe EAE characterized by leukocytic infiltration and demyelination in the brain, spinal cord and optic nerve. Notably, while the frequency of CD4⁺ T cells was increased in the CNS of IgH[MOG] with severe disease relative to controls, no differences were observed with respect to the frequency of B cells. Further, IgH[MOG] CNS-

infiltrating CD4⁺ T cells produced significantly higher levels of Th17-associated cytokines GM-CSF and IL-17 compared to those from controls. Mechanistically, IgH[MOG] B cells were better able than WT B cells to elicit inflammatory cytokine production from MOG_[35-55]-specific CD4⁺ T cells in *in vitro* priming assays.

CONCLUSION: These data show that MOG-specific B cells contribute to CD4⁺ T cell-driven EAE by promoting CD4⁺ T cell inflammation and recruitment to the CNS.

Keywords: experimental autoimmune encephalomyelitis, B cell, CD4⁺ T cell, myelin oligodendrocyte glycoprotein (MOG), IgH[MOG], 1C6, non-obese diabetic (NOD)

Background

Multiple sclerosis (MS) is a chronic neurodegenerative disease in which the adaptive immune system launched an attack against central nervous system (CNS) proteins, such as myelin, ultimately resulting in neurological dysfunction and death. MS affects more than 2 million people worldwide [1]. Approximately 80% of patients present an initially relapsing-remitting (RR) disease course for which there are now more than 10 disease-modifying therapies available. However, 30-60% of these (RR) patients will eventually transition to a chronically worsening secondary progressive (SP) phase, for which treatment options are limited [2]. Pathophysiological mechanisms in progressive MS are thus of intense current interest [3].

T cells, and CD4⁺ T cells in particular, have been the most intensively studied players in the immune pathogenesis of MS. However, it has become increasingly clear that B cells additionally play important roles in MS pathogenesis. Clonally expanded B cells are present in the cerebrospinal fluid (CSF) and MS plaques [4-6], and the presence of meningeal follicles adjacent to cortical lesions is associated with disease progression [7,8]. Further, antibodies against myelin oligodendrocyte glycoprotein (MOG), a key component of myelin, were found in active MS lesions [9]. Crucially, the B cell targeting reagent ocrelizumab (anti-CD20) results in striking improvements in RR-MS, and is the only FDA approved drug for primary progressive MS [10,11]. Intriguingly, antibody-secreting B cells do not express CD20 [12]. This suggests that the principal pathogenic role of B

cells in MS might be unrelated to the generation of autoantibodies, and rather to their capacity to interact with other immune cell types, such as T cells.

Experimental autoimmune encephalomyelitis (EAE) is an animal disease that models many of the immune aspects of MS pathogenesis. Use of this model has helped us to understand the role of T cells, and CD4⁺ T cells in particular, in the initiation and maintenance of autoreactive inflammation in the CNS [13]. However, studies using the transgenic IgH[MOG] mouse strain have indicated that B cells may also play a crucial role in EAE pathology. These mice express a knock-in transgenic IgH chain derived from a MOG-specific antibody; thus, around 30% of their B cells are therefore specific for MOG protein [14]. IgH[MOG] animals develop severe EAE when immunized with either whole MOG protein [14] or with its extracellular domain (MOG_[1-125])[15], indicating an important role for MOG-reactive B cells in neuroimmune processes. However the potential mechanisms by which MOG-reactive B cells facilitate T cell-driven pathogenicity, such as in class II-restricted peptide immunization models of EAE, remain incompletely understood.

Here, we studied the co-operative role of B cells and T cells in CNS autoimmunity using IgH[MOG] mice on the non-obese diabetic (NOD) genetic background. We immunized these, and wildtype (WT) NOD mice, with MOG_[35-55], a MHC class II-restricted peptide that obligatorily drives a CD4⁺ T cell response. While WT NOD mice gradually develop a relapsing chronic form of EAE over the course of 80-100 days when immunized with MOG_[35-55] [16], we observed that IgH[MOG] mice developed a severe form of EAE within 14 days that was

characterized by demyelination and inflammation of the CNS. Disease in these animals was accompanied by an increase in CNS-infiltrating T cells that expressed higher levels of the inflammatory cytokines IL-17 and GM-CSF as compared to wildtype controls. Importantly, IgH[MOG] B cells could prime MOG_[35-55]-reactive T cells to produce increased inflammatory cytokines *in vitro*. Hence, we demonstrate that the collaborative role of B cells and T cells are important for severe CNS autoimmunity.

Methods

Animals

IgH[MOG] mice on the NOD background were a gift from Dr. Hartmurt Wekerle and 1C6 mice were a gift from Dr. Vijay Kuchroo. NOD/ShiLtJ mice were purchased from Jackson Laboratories. The sex of the mice used is indicated in each figure legend.

EAE induction and scoring

NOD and IgH[MOG] mice were immunized subcutaneously with 200µg MOG_[35-55] (Feldan), emulsified in incomplete Freund's adjuvant (BD Difco) that was supplemented with 500 µg *M. tuberculosis* extract (BD Difco). On day 0 and day 2 post-immunization, mice received 200 ng pertussis toxin (List Biological Laboratories) intraperitoneally. Mice were monitored daily for signs of EAE, which were assessed using a semi-quantitative 0-5 scale: 0; no disease, 0.5; ruffled fur,

1; limp tail, 1.5; mild impairment in gait, 2; severe impairment in gait, 2.5; partial hind limb paralysis, 3; hind limb paralysis, 4; forelimb paralysis, 5; moribund [17]. Pre-onset analyses were conducted a minimum of 5 days post-immunization but before the onset of symptoms. Endpoint analyses were conducted at d14.

Histopathology

EAE mice were euthanized, and CNS tissue and optic nerves were immediately fixed in 4% paraformaldehyde solution. After 24 hours, the tissues were transferred into PBS for paraffin embedding. Paraffin embedded sections were made at 4 µm thickness and stained with Hematoxylin & Eosin (H&E) to detect the infiltration of immune cells, or Luxol fast blue (LFB) to detect demyelination. The images were taken at 10X and 20X magnifications with Nikon Eclipse 80i microscope and were analysed using ImageJ software (NIH).

Measurement of serum immunoglobulin

Blood samples were collected from NOD and IgH[MOG] unimmunized mice, as well as from immunized mice at pre-onset and experimental endpoint, in an EDTA-coated Microvette (Sarstedt). They were centrifuged at 2000g for 20 minutes at 4°C to obtain plasma. The concentration of plasma IgM was analysed using the HRP C57BL/6J Mouse Clonotyping System (Southern Biotech) according to the manufacturer's instructions.

Isolation of CNS-infiltrating mononuclear cells

Mice were euthanized and perfused intracardially with PBS. Brain and spinal cord were dissected from the skull and vertebral column respectively and were prepared as previously described [17]. Briefly, CNS tissues were digested with liberase (Roche) and DNase I (Sigma) and cells were enriched using a 35% Percoll (GE Healthcare) gradient.

Flow cytometry

Single cell suspensions were obtained from spleens, lymph nodes and CNS of EAE mice. For detection of surface antigens, cells were stained with Fixable Viability Dye (eBioscience) and incubated with Fc Block (Biolegend) prior to staining with antibodies against surface antigens (CD45, CD4, CD8, CD19, CD11b, CD11c, Ly6G; details in following section). For detection of intracellular cytokines, cells were first stimulated with 50ng ml⁻¹ PMA (Sigma), 1μM ionomycin (Sigma) and 1μL mL⁻¹ GolgiStop (BD) for 4 hours at 37°C, prior to being labeled with viability indicator, Fc Block and relevant surface antigens as above. They were then fixed and permeabilized (Fixation Buffer and Intracellular Staining Perm Wash Buffer, both Biolegend) and stained for intracellular cytokines (IFN-γ, TNF-α, IL-17A, GM-CSF; details in following section). Samples were analyzed on a FACS Aria (BD) and data were analyzed using FlowJo software (Treestar).

Flow cytometry antibodies

The following monoclonal antibodies against mouse antigens were used: CD45, clone A20 (Biolegend); CD11b, clone M1/70 (eBioscience); CD11c, clone N418 (Biolegend); Ly6G, clone 1A8 (BD Biosciences); CD4, clone RM4-5 (eBioscience); CD8, clone 53-6.7 (Biolegend); CD19, clone 1D3 (eBioscience); IFN- γ , clone XMG1.2 (eBioscience); TNF- α , clone MP6-XT22 (eBioscience); IL-17a, clone TC11-18H10.1 (Biolegend); GM-CSF, clone MP1-22E9 (eBioscience); CD40, clone 3/23 (Biolegend); CD80, clone 1610A1 (Biolegend).

Antigen presentation assay

Single cell suspensions were obtained from the spleens of unimmunized NOD and IgH[MOG] mice. Cells were labeled with CD43 (Ly-48) Microbeads (Miltenyi), and CD43⁺ leukocytes (all leukocytes except resting B cells) were depleted on a magnetic MACS column (Miltenyi). Unlabelled CD43⁻ cells were collected and were subsequently stained with anti-mouse CD19. CD19⁺ B cells were purified using high-speed cell sorting. In parallel, CD4⁺ T cells were purified from the spleens of 1C6 mice using mouse CD4 MicroBeads (Miltenyi) and labeled with CellTrace Violet (CTV; Thermo Fisher Scientific). CTV-labeled 1C6 CD4⁺ T cells were cultured with B cells at a ratio of 1 CD4: 1 B, with 0, 1 or 10 μ g ml⁻¹ MOG_[35-55] for 72 hours. CTV dilution and intracellular cytokine production were assessed by flow cytometry.

Statistical analysis

For comparison of EAE scores on individual days, Mann-Whitney *U* test was used. Fisher's exact test was used to measure the frequency of mice attaining ethical endpoints. For immunoglobulin analyses and *ex vivo* cytokine profiling, unpaired Student *t*-tests were used. For cytokine production in the *in vitro* priming experiment, two way ANOVA was used. Two-tailed analyses were used in all instances. All statistical analyses were conducted using Prism software (GraphPad).

Results

IgH[MOG] mice develop severe EAE upon active immunization with MOG_[35-55]

When immunized with MOG_[35-55], wildtype (WT) NOD strain gradually develop an initial relapse remitting pattern that ultimately transitions to a chronically worsening phase over the course of 60-100 days [16]. NOD-EAE has thus been considered a possible model of SPMS [18,19]. To assess whether the presence of substantial numbers of MOG-reactive B cells could alter this disease pattern, we immunized IgH[MOG] and NOD controls with MOG_[35-55]. Strikingly, immunized IgH[MOG] mice rapidly developed severe EAE within 14 days (Figure 1), while WT NOD mice either were disease-free or had only mild symptoms at this timepoint (mean maximal severity, 3.1 ± 0.2 for IgH[MOG], $n=27$; 0.07 ± 0.07 for WT NOD, $n=19$; $p<0.0001$). Strikingly, 55% of immunized IgH[MOG] mice (15/27) attained ethical endpoints and had to be euthanized by d14; no WT NOD

attained disease of this severity (0/19; $p < 0.0001$). For the remainder of the study, d14 was therefore treated as the endpoint of immunization protocols.

We next examined CNS tissue damage in actively immunized mice. Immunized IgH[MOG] mice displayed immune infiltration the cerebellum (Figure 2A) and pons (Figure 2B), as well as the spinal cord (Figure 2C) and optic nerve (Figure 2D). Demyelination was also observed in these tissues (Figures 2E-H). By contrast, there was little to no infiltration or demyelination of CNS tissue observed in immunized WT NOD mice sacrificed in parallel. Our data thus show that the presence of myelin-reactive B cells can exacerbate CNS autoimmunity and tissue damage when EAE is induced in a $CD4^+$ T cell dependent manner.

Decrease in plasma IgM in immunized IgH[MOG] mice

Antigen-specific antibody (Ab) secretion is the primary function of B cells. Further, oligoclonal immunoglobulin (Ig) banding in cerebrospinal fluid (CSF) is an important diagnostic marker for MS [20]. Upon initial activation, B cells first secrete antigen-specific Abs of the IgM isotype [21]. The Ab secreted by a given B cell clone can later “switch” to a different isotype based on the presence of differentiation cues in the local milieu, such as cytokines secreted by T cells [22]. We therefore wanted to examine whether changes in total serum IgM might reflect the rapid nature of the disease observed in IgH[MOG] mice. We collected sera from immunized NOD versus IgH[MOG] at pre-onset (PO) and at disease endpoint (EP), and additionally from unimmunized (UI) mice of both strains. We then analyzed these sera for the presence of IgM. We found that the

concentration of plasma IgM levels was significantly reduced in IgH[MOG] mice at endpoint relative to NOD controls, indicative of increased switching to secondary isotype subclasses in the context of severe disease (Figure 3). These data indicated that exacerbated disease in IgH[MOG] mice is accompanied by isotype class switching and therefore pointed towards the potential collaboration of MOG-reactive B cells with other immune cell types.

Increased presence of immune cells in the CNS of immunized IgH[MOG] mice.

We next wanted to examine whether there were differences between NOD and IgH[MOG] mice in the composition of the immune cells infiltrating the CNS. We first sacrificed mice at the pre-onset stage (d5-post immunization) and analyzed the percentage of immune cells (CD19⁺ B cells, CD4⁺ T cells, CD8⁺ T cells, CD11b⁺CD11c⁺ dendritic cells, CD11b⁺CD11c⁻Ly6G⁻ macrophages and CD11b⁺Ly6G⁺ neutrophils) in both CNS and spleen. At this early timepoint, differences in the frequency of such cells were modest in both CNS (Figure 4A) and spleen (Figure 4B), although we did observe an increase in the relative proportion of macrophages infiltrating the CNS of IgH[MOG] mice (Figure 4A).

We then assessed the frequency of immune cell proportions at disease endpoint (d14). Strikingly, the proportion of CD4⁺ T cells was significantly increased in the CNS of IgH[MOG] mice relative to NOD (Figure 4C). CD8⁺ T cells, dendritic cells and neutrophils were also more prevalent in the CNS of IgH[MOG] (Figure 4C), though overall frequency of these cells were low in all mice studied (<5%). The frequency of CD4⁺ T cells was also higher in the

spleens of IgH[MOG] mice at endpoint, suggesting their expansion in these animals (Figure 4D). Interestingly, despite having an antigenic repertoire heavily skewed towards MOG reactivity, immunized IgH[MOG] mice did not display an increased frequency of B cells in either the CNS (Figure 4C) or spleen (Figure 4D) at endpoint. These findings suggested that while IgH[MOG] B cells might be important in driving T cell expansion and infiltration into the CNS, they might themselves be of secondary importance to the development of severe EAE in IgH[MOG] mice.

CNS-infiltrating IgH[MOG] CD4⁺ T cells produce increased levels of IL-17 and GM-CSF.

As we had observed an elevated frequency of CD4⁺ T cells in the CNS of sick IgH[MOG] mice, we next examined the capacity of these cells to produce inflammatory Th1 and Th17 cytokines by flow cytometry, due to the well-established role of these CD4⁺ effector T cell subsets in EAE [23]. We observed no differences between IgH[MOG] and WT CD4⁺ T cells in their production of the Th1 signature cytokine IFN- γ in the CNS (Figure 5A). By contrast we saw a striking upregulation of IL-17 production from CNS-infiltrating CD4⁺ T cells from IgH[MOG] at disease endpoint (Figure 5B). Notably, production of GM-CSF, a key pathogenic cytokine implicated in Th17-driven tissue inflammation, was also augmented in IgH[MOG] CD4⁺ T cells (Figure 5C), though no differences were noted in the production of TNF α (Figure 5D). In sum, our data showed that Th17

cells were preferentially recruited to the CNS of IgH[MOG] mice with severe EAE.

IgH[MOG] B cells have an augmented capacity to prime inflammatory MOG_[35-55]-specific CD4⁺ T cells

Thus far, we had found evidence of increased expansion and cytokine production from CD4⁺ T cells in IgH[MOG] mice. As B cells can express MHC class II and are thus capable of presenting antigen to CD4⁺ T cells [24], we wanted to assess whether IgH[MOG] B cells intrinsically possess an enhanced capacity to prime MOG_[35-55]-specific T cell responses. We purified splenic B cells from unimmunized IgH[MOG] or WT NOD mice and, in the presence or absence of MOG_[35-55], co-cultured these cells with antigen-inexperienced CD4⁺ T cells from transgenic 1C6 mice. 1C6 mice are on the NOD background and have class II-restricted T cell receptor specificity to MOG_[35-55] [25]. IgH[MOG] and WT B cells did not differ in their capacity to induce CD4⁺ T cell proliferation in response to MOG_[35-55] (Figure 6A). However, IgH[MOG] B cells elicited a greater frequency of CD4⁺ T cells that expressed IFN- γ , IL-17, and the autocrine T cell growth factor IL-2 (Figure 6B). Altogether, our findings indicated that IgH[MOG] B cells may shape the initial Ag-specific activation of T cells by promoting their generation of inflammatory cytokines.

Discussion

The role of CD4⁺ T cells in the autoimmune pathogenesis of MS is well-established. Notably, genome-wide association studies (GWAS) have revealed that polymorphisms in the human leukocyte antigen class II region, which restricts the CD4⁺ T cell repertoire, are strongly associated with MS susceptibility [26]. Further, many of the current treatments of MS are believed to target T cell responses [27-29]. However, the success of the B cell-depleting drug ocrelizumab in both RRMS and PPMS has intensified recent interest in the contribution of B cells to disease processes [30].

IgH[MOG] mice were initially described on the C57BL/6 (B6) and SJL/J genetic backgrounds. On the B6 background, IgH[MOG] mice showed an increased incidence of EAE, relative to WT, when immunized with whole MOG protein [14]. Intriguingly, IgH[MOG] SJL/J mice developed EAE of greater severity than controls when immunized with the myelin-derived epitope proteolipid protein (PLP)_[139-154] [14], which induces a relapsing/remitting disease pattern in SJL/J background mice [31]. This suggested that the presence of MOG-reactive B cells could contribute to EAE pathology that was driven by a class II-restricted peptide; however, the nature of a putative collaboration between B cells and T cells in disease processes remained incompletely defined.

In our study, we actively immunized IgH[MOG] mice on NOD background with the class II restricted peptide MOG_[35-55]. This permitted us to study the contribution of MOG-reactive B cells in a model of EAE that is initiated by CD4⁺ T

cells. While WT NOD mice developed a gradual, chronic MOG_[35-55]-driven disease course, with severe symptoms appearing only many weeks after immunization, we found that 80% of IgH[MOG] NOD mice develop severe and frequently lethal disease within 14 days, that was characterized by inflammation and demyelination in brain, optic nerve and spinal cord. Cellular characterization of mononuclear infiltrate showed an increased frequency of CD4⁺ T cells, but not B cells, in the CNS of IgH[MOG] relative to controls. It was previously shown that IgH[MOG] x 1C6 double-transgenic mice on the NOD background develop spontaneous EAE, while single-transgenic IgH[MOG] or 1C6 mice do not [25]. These findings indicated that the collaboration of both myelin-specific B and T cells in the same animal could induce CNS autoimmunity; however, it was difficult to determine whether B or T cell-driven responses were initially responsible for disease induction in this model. Here, by using a myelin-derived, class II-restricted, immunogen, we show that B cells augment EAE even when CD4⁺ T cells initiate disease.

Intriguingly, CNS-infiltrating IgH[MOG] CD4⁺ T cells generated significant amounts of the type-17 cytokines IL-17 and GM-CSF. Several lines of evidence indicate that Th17 cells can shape B cell responses *in vivo*. Adoptive transfer of myelin-specific Th17 cells induced both B cell isotype class switching and germinal center formation in an IL-17-dependent manner [32]. Further, Th17 cells are crucial for the development of B cell-rich ectopic lymphoid structures [33,34], which are associated with rapid acceleration of the disease. Here, our data

suggest that the inverse may also be true and that B cells may reinforce and augment Th17-mediated pathogenicity in the CNS.

A key antibody independent function of B cells is the antigen presentation to T cells, and B cells are particularly efficient at presenting their cognate antigen [35]. Interestingly, we found that in the presence of MOG_[35-55], IgH[MOG] B cells were better able than WT B cells to induce the production of inflammatory cytokines from MOG_[35-55]-reactive CD4⁺ T cells. These findings are broadly in line with previous observations that splenocytes from 1C6 x IgH[MOG] mice showed enhanced responses to MOG_[35-55] relative to splenocytes from 1C6 single-transgenic animals [25], and they demonstrate that MOG-specific B cells have a greater intrinsic capacity to induce the differentiation of cognate antigen specific T cells. B cell antigen presentation plays a crucial role in autoimmune responses to whole MOG protein, as mice specifically lacking MHC class II expression on B cells (B-MHC-II^{-/-}) are resistant to human MOG-induced EAE [24]. Notably, however, B-MHC-II^{-/-} mice develop EAE in response to MOG_[35-55]. Thus, in mice with an unbiased B cell repertoire, B cell-dependent antigen presentation to T cells may play an important role in the processing and presentation of secondary MOG-derived epitopes. However, when a large frequency of MOG-reactive B cells are initially present, as is the case in IgH[MOG] mice, antigen presentation of MOG_[35-55] itself by B cells may exacerbate disease severity.

Conclusion

In this study, we provide evidence that in the presence of a B cell repertoire that is skewed towards MOG, NOD background mice develop unusually severe EAE upon immunization with the classic class II-restricted peptide MOG_[35-55]. Disease is characterized by an influx of highly inflammatory CD4⁺ T cells into the CNS. Our findings support a role for myelin-reactive B cells in augmenting T cell-driven CNS autoimmunity.

Abbreviations

Ab, antibody; CNS, central nervous system; CSF, cerebrospinal fluid; CTV, CellTrace Violet; EAE, experimental autoimmune encephalomyelitis; EP, endpoint; GM-CSF, granulocyte and macrophage colony stimulating factor; H&E, hematoxylin & eosin; IFN, interferon; Ig, immunoglobulin; IL, interleukin; LFB, Luxol fast blue; MHC, major histocompatibility complex; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; NOD, non-obese diabetic; PLP, proteolipid protein; preonset, PO; RR, relapsing/remitting; SP, secondary progressive; TNF, tumor necrosis factor; UI, unimmunized; WT, wildtype

Declarations

Ethics approval

All mouse breedings and experiments are approved by the Animal Protection Committee of the Centre de recherche du CHU de Quebec - Université Laval (protocols 13-070-2 and 17-090-2).

Consent for publication

Not applicable

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Competing interests

The authors declare no competing interests.

Funding

The work was supported by a Biomedical Operating Grant from the MS Society of Canada (#3036) to MR. PMIAD is supported by a doctoral studentship from the Multiple Sclerosis Society of Canada and PG holds a Ph.D. fellowship from the Fonds recherche du Québec – Santé (FRQS). NB is Junior-1 scholar, and MR is a Junior-2 scholar, of the FRQS.

Authors' contributions

PMIAD directed the project, conducted experiments and wrote the manuscript. APY and JB conducted experiments. BM and SL conducted histological analyses. PG and NB assisted with serum detection of immunoglobulins. MR supervised the project and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Hartmut Wekerle and Vijay Kuchroo for providing us with IgH[MOG] and 1C6 mice respectively. We thank Alexandre Brunet and Stéphanie Fiola for technical assistance with flow cytometry and Andre Machado Xavier for ImageJ analysis.

Figure legends

Figure 1. Active immunization with MOG_[35-55] induces severe EAE in IgH[MOG] mice. Female IgH[MOG] (n=10) and WT NOD (n=8) were immunized with MOG_[35-55] and were monitored for the development of EAE. IgH[MOG], n=10; NOD, n=8. ** p<0.01, Mann-Whitney *U* test. Representative of 3 experiments and a total of 27 IgH[MOG] and 19 NOD.

Figure 2. Immune cells infiltrated into the CNS of IgH[MOG] mice and caused demyelination. CNS tissues from an immunized female IgH[MOG] recipient were isolated once it reached experimental endpoints, and H&E (**A-D**) and hematoxylin and Luxol fast blue (**E-H**) stainings were conducted. Cerebellum (**A, E**) and pons (**B, F**), 10 X magnification; spinal cord (**C, G**) and optic nerve (**D, H**), 20X magnification. Scale bar: 100µm. Representative of 5 mice.

Figure 3. Decrease in plasma IgM in immunized IgH[MOG] mice. Plasma were collected from the blood of female NOD or IgH[MOG] mice that were unimmunized (UI) NOD or from MOG_[35-55]-immunized NOD or IgH[MOG] mice at pre-onset (PO) or disease endpoint (EP). Plasma IgM levels were measured. * $p < 0.05$, t -test. IgH[MOG], $n=4$; NOD, $n=5$.

Figure 4. Increased infiltration of peripheral immune cells in the CNS of immunized IgH[MOG] mice. **A, B.** IgH[MOG] ($n=5$) and WT NOD ($n=5$) female mice were immunized with MOG_[35-55], sacrificed at d5, and CNS (**A**) and Splenic (**B**) immune populations (CD4⁺ T cells, CD8⁺ T cells, CD11c⁺CD11b⁺ dendritic cells, CD11c⁻Ly6G⁻CD11b⁺ macrophages and Ly6G⁺CD11b⁺ neutrophils) were enumerated. **C, D.** IgH[MOG] ($n=13$) and WT NOD ($n=8$) female mice were immunized with MOG_[35-55] and sacrificed at d14. CNS-infiltrating (**C**) and splenic (**D**) immune cells were enumerated. * $p < 0.05$, ** $p < 0.001$, *** $p < 0.0005$, **** $p < 0.0001$, t -test n.s., not significant.

Figure 5. CNS-infiltrating IgH[MOG] CD4⁺ T cells produce increased levels of IL-17 and GM-CSF. IgH[MOG] (n=5) and WT NOD (n=5) female mice were immunized with MOG_[35-55] and sacrificed at disease endpoints. Production of IFN γ (A), IL-17 (B), GM-CSF (C) and TNF α (D) was assessed by intracellular flow cytometry from CNS-infiltrating CD4⁺ T cells. * p<0.05, ** p<0.005, t-test.

Figure 6. B cells from IgH[MOG] are better antigen presenting cells to CD4⁺ T cells. B cells from male IgH[MOG] or NOD mice were co-cultured with CellTrace Violet-labeled CD4⁺ T cells from male 1C6 mice, and with 0,1 or 10 μ g/ml MOG_[35-55]. Cell proliferation (A) and the production of IFN γ , IL-17 and IL-2 (B) by CD4⁺ T cells were assessed using flow cytometry. Gating percentage in (A) corresponds to the percentage of cells that underwent at least one division. B, * p<0.05, ** p<0.01, *** p<0.001, two way ANOVA measuring the effect of mouse strain (NOD vs. IgH[MOG]) as a variable. Triplicate cultures, representative of three experiments.

References

1. Kingwell E, Marriott JJ, Jetté N, Pringsheim T, Makhani N, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC neurology [Internet]. BioMed Central; 2013;13:128. Available from: <http://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-13-128>
2. Larochelle C, Uphaus T, Prat A, Zipp F. Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology? Trends in Neurosciences. 2016;39:325–39.
3. Thompson A. Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. Mult. Scler. [Internet]. 2004;10 Suppl 1:S2–7. Available from:

- 493 <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=1521880>
494 [3&retmode=ref&cmd=prlinks](http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=1521880)
- 495 4. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR.
496 B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions.
497 J. Immunol. [Internet]. 1999;163:5133–44. Available from:
498 <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=1052822>
499 [0&retmode=ref&cmd=prlinks](http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=1052822)
- 500 5. Owens GP, Kraus H, Burgoon MP, Smith-Jensen T, Devlin ME, Gilden DH.
501 Restricted use of VH4 germline segments in an acute multiple sclerosis brain.
502 Ann. Neurol. [Internet]. 1998;43:236–43. Available from:
503 <http://doi.wiley.com/10.1002/ana.410430214>
- 504 6. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH.
505 Single-cell repertoire analysis demonstrates that clonal expansion is a prominent
506 feature of the B cell response in multiple sclerosis cerebrospinal fluid. J.
507 Immunol. [Internet]. 2003;171:2725–33. Available from:
508 <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=1292842>
509 [6&retmode=ref&cmd=prlinks](http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=1292842)
- 510 7. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al.
511 Meningeal B-cell follicles in secondary progressive multiple sclerosis associate
512 with early onset of disease and severe cortical pathology. Brain. 2007;130:1089–
513 104.
- 514 8. Uccelli A, Aloisi F, Pistoia V. Unveiling the enigma of the CNS as a B-cell
515 fostering environment. Trends Immunol. [Internet]. 2005;26:254–9. Available
516 from: <https://linkinghub.elsevier.com/retrieve/pii/S1471490605000487>
- 517 9. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies
518 associated with myelin damage in multiple sclerosis. Nature Publishing Group;
519 1999;5:170–5. Available from: http://www.nature.com/articles/nm0299_170
- 520 10. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, et al.
521 Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised,
522 placebo-controlled, multicentre trial. Lancet [Internet]. 2011;378:1779–87.
523 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673611616498>
- 524 11. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al.
525 Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N. Engl.
526 J. Med. 2016.
- 527 12. Lehmann-Horn K, Kronsbein HC, Weber MS. Targeting B cells in the
528 treatment of multiple sclerosis: recent advances and remaining challenges.
529 SAGE Publications; 2013;6:161–73. Available from:
530 <http://tan.sagepub.com/cgi/doi/10.1177/1756285612474333>

- 531 13. Rangachari M, Kuchroo VK. Using EAE to better understand principles of
532 immune function and autoimmune pathology. *J. Autoimmun.* 2013.
- 533 14. Litzemberger T, Fässler R, Bauer J, Lassmann H, Linington C, Wekerle H, et
534 al. B lymphocytes producing demyelinating autoantibodies: development and
535 function in gene-targeted transgenic mice. *J. Exp. Med.* 1998;188:169–80.
- 536 15. Dang AK, Jain RW, Craig HC, Kerfoot SM. B cell recognition of myelin
537 oligodendrocyte glycoprotein autoantigen depends on immunization with protein
538 rather than short peptide, while B cell invasion of the CNS in autoimmunity does
539 not. *J. Neuroimmunol.* 2015;278:73–84.
- 540 16. Encinas JA, Wicker LS, Peterson LB, Mukasa A, Teuscher C, Sobel R, et al.
541 QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM
542 region containing *Il2*. *Nat. Genet.* 1999;21:158–60.
- 543 17. Boivin N, Baillargeon J, Doss PMIA, Roy A-P, Rangachari M. Interferon- β
544 suppresses murine Th1 cell function in the absence of antigen-presenting cells.
545 *PLoS ONE.* 2015;10:e0124802.
- 546 18. Mayo L, Cunha APD, Madi A, Beynon V, Yang Z, Alvarez JI, et al. IL-10-
547 dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central
548 nervous system inflammation. *Brain.* 2016;139:1939–57.
- 549 19. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL. Toll-
550 like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous
551 system neuroinflammation in progressive EAE. *Nature Publishing Group*;
552 2009;10:958–64. Available from:
553 <http://www.nature.com/doi/10.1038/ni.1775>
- 554 20. Obermeier B, Mentele R, Malotka J, Kellermann J, Kümpfel T, Wekerle H, et
555 al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of
556 cerebrospinal fluid in multiple sclerosis. *Nature Publishing Group*; 2008;14:688–
557 93. Available from: <http://www.nature.com/articles/nm1714>
- 558 21. Racine R, Winslow GM. IgM in microbial infections: taken for granted?
559 *Immunol. Lett.* [Internet]. 2009;125:79–85. Available from:
560 <https://linkinghub.elsevier.com/retrieve/pii/S016524780900162X>
- 561 22. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL,
562 Mosmann TR, et al. Regulation of antibody isotype secretion by subsets of
563 antigen-specific helper T cells. *Nature* [Internet]. *Nature Publishing Group*;
564 1988;334:255–8. Available from: <http://www.nature.com/articles/334255a0>
- 565 23. Domingues HS, Mues M, Lassmann H, Wekerle H, Krishnamoorthy G.
566 Functional and pathogenic differences of Th1 and Th17 cells in experimental
567 autoimmune encephalomyelitis. *PLoS ONE.* 2010;5:e15531.

- 568 24. Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod'homme T,
569 Varrin-Doyer M, et al. MHC class II-dependent B cell APC function is required for
570 induction of CNS autoimmunity independent of myelin-specific antibodies. *J. Exp.*
571 *Med.* 2013;210:2921–37.
- 572 25. Anderson AC, Chandwaskar R, Lee DH, Sullivan JM, Solomon A, Rodriguez-
573 Manzanet R, et al. A transgenic model of central nervous system autoimmunity
574 mediated by CD4+ and CD8+ T and B cells. *J. Immunol.* 2012;188:2084–92.
- 575 26. Field J, Browning SR, Johnson LJ, Danoy P, Varney MD, Tait BD, et al. A
576 polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple
577 sclerosis. Andreu AL, editor. *PLoS ONE* [Internet]. Public Library of Science;
578 2010;5:e13454. Available from: <http://dx.plos.org/10.1371/journal.pone.0013454>
- 579 27. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation
580 and interferon gamma production in multiple sclerosis. *J. Neuroimmunol.*
581 1993;46:145–53.
- 582 28. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate
583 (Copaxone) induces degenerate, Th2-polarized immune responses in patients
584 with multiple sclerosis. *J. Clin. Invest.* [Internet]. American Society for Clinical
585 Investigation; 2000;105:967–76. Available from:
586 <http://www.jci.org/articles/view/8970>
- 587 29. Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, et al. Altered
588 CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients
589 with multiple sclerosis. *Arch. Neurol.* [Internet]. American Medical Association;
590 2006;63:1383–7. Available from:
591 <http://archneur.jamanetwork.com/article.aspx?doi=10.1001/archneur.63.10.1383>
- 592 30. Myhr K-M, Torkildsen Ø, Lossius A, Bø L, Holmøy T. B cell depletion in the
593 treatment of multiple sclerosis. *Expert Opin Biol Ther.* 2019;19:261–71.
- 594 31. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases:
595 implications for immunotherapy. *Nature Publishing Group*; 2002;2:85–95.
596 Available from: <http://www.nature.com/doifinder/10.1038/nri724>
- 597 32. Mitsdoerffer M, Lee Y, Jäger A, Kim H-J, Korn T, Kolls JK, et al.
598 Proinflammatory T helper type 17 cells are effective B-cell helpers. *Proc. Natl.*
599 *Acad. Sci. U.S.A.* [Internet]. National Academy of Sciences; 2010;107:14292–7.
600 Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.1009234107>
- 601 33. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B, et al.
602 Th17 cells induce ectopic lymphoid follicles in central nervous system tissue
603 inflammation. *Immunity.* 2011;35:986–96.
- 604 34. Pikor NB, Astarita JL, Summers-Deluca L, Galicia G, Qu J, Ward LA, et al.
605 Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-

606 Resident Stromal Cell Remodeling to Propagate Neuroinflammation. *Immunity*.
607 2015;43:1160–73.

608 35. Batista FD, Harwood NE. The who, how and where of antigen presentation to
609 B cells. *Nat. Rev. Immunol.* 2009;9:15–27.

610

Figure 1

bioRxiv preprint doi: <https://doi.org/10.1101/721696>; this version posted August 1, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 2

bioRxiv preprint doi: <https://doi.org/10.1101/721698>; this version posted August 1, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 3

Figure 4

Figure 5

CNS

NOD IgH[MOG]

A.

B.

C.

D.

bioRxiv preprint doi: <https://doi.org/10.1101/721696>; this version posted August 1, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 6

A. B.

NOD

IgH[MOG]

B.